https://www.hcplive.com/view/dapagliflozin-slows-rate-kidney-decline
In a late-breaking abstract presented at ASN 2022, dapagliflozin attenuated the decline in eGFR between month 1-36 compared to placebo.
Create an account or login to join the discussion